# Study to Evaluate the Efficacy and Safety of Selonsertib in Participants With Moderate to Advanced Diabetic Kidney Disease

> **NCT04026165** · PHASE2 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 384 (actual)

## Conditions studied

- Diabetic Kidney Disease

## Interventions

- **DRUG:** SEL
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04026165
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-07-24
- **Primary completion:** 2021-09-03
- **Final completion:** 2021-09-03
- **Target enrollment:** 384 (ACTUAL)
- **Last updated:** 2022-12-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04026165

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04026165, "Study to Evaluate the Efficacy and Safety of Selonsertib in Participants With Moderate to Advanced Diabetic Kidney Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04026165. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*